AstraZeneca to cap US out-of-pocket costs for inhalers at $35 per month, ET HealthWorld
London: AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States, starting June, following a similar move ...
